Drugdocs | Natroba®

Drug updated on 4/10/2024

Dosage Form	Suspension (topical; 0.9%)
Drug Class	Antiparasitic agents
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

For the topical treatment of head lice infestations in adult and pediattic patients 6 months of age and older.

For the topical treatment of scabies infestations in adult and pediatric 4 years of age older.

Spinosad (Natroba) is indicated for the topical treatment of head lice and scabies infestations in adults and pediatric patients, with age restrictions varying between 6 months to 4 years depending on the condition.
The study was derived from a randomized controlled trial.
In terms of efficacy, Spinosad showed significant results compared to placebo. Approximately 78.1% of the subjects treated with Spinosad achieved complete cure by day 28 post-treatment as opposed to only 39.6% in the placebo group.
Safety-wise, no adverse effects were reported among study participants, indicating that it is well-tolerated and safe for use in treating scabies infestations.
Although direct comparisons with other treatments are not provided within this study, it suggests potential advantages over approved products due to its natural source, reducing chances of resistance development.
The study tested Spinosad on both adult and pediatric patients aged four years or older, suggesting its applicability across various age groups; however, detailed subgroup analysis data isn't available, limiting insight into differential efficacy or safety profiles within subgroups.

Document Title	Year	Source
Natroba (spinosad) Prescribing Information.	2021	ParaPRO LLC, Carmel, IN

Document Title	Sex Distribution	Year	Source
Spinosad at 0.9% in the treatment of scabies: Efficacy results from 2 multicenter, randomized, double-blind, vehicle-controlled studies.	206Subjects F: 57% M: 43%	2022	Journal of the American Academy of Dermatology

Document Title

Sex Distribution:

F:57%

M:43%

206Subjects

Year:

2022

Source:Journal of the American Academy of Dermatology